FROM THE LABS: Long-term survival supports the potential benefit of CAR T cell therapy to treat solid tumors
An 18-year survivor of neuroblastoma is believed to represent the longest reported remission to date in a patient treated with chimeric antigen receptor (CAR) T cell therapy.
Read More